Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 6/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.38 |
| ▸ | SCD | O00767 | 1/20 | 0.38 |
| ▸ | WNT1 | P04628 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 3/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20162147 | 0.87 | CYP3A4 (0.43) | RIPK1HTR2CHTR2BSCDMMP13 | |
| SCHEMBL20364380 | 0.87 | TAS2R8 (0.54) | TAS2R8RIPK1WNT1GSK3BDYRK1A | |
| SCHEMBL20364373 | 0.85 | TAS2R8 (0.41) | TAS2R8RIPK1HTR2CHTR2BCDK5 | |
| SCHEMBL20364379 | 0.85 | TAS2R8 (0.54) | TAS2R8WNT1GSK3BDYRK1AMAP3K5 | |
| SCHEMBL20364374 | 0.83 | TAS2R8 (0.44) | TAS2R8RIPK1HTR2CHTR2BCDK5 | |
| SCHEMBL20162172 | 0.83 | TAS2R8 (0.35) | TAS2R8RIPK1CDK5CDK5R1WNT1 | |
| SCHEMBL20364375 | 0.82 | PNMT (0.42) | TAS2R8RIPK1CDK5CDK5R1 | |
| SCHEMBL20364377 | 0.82 | NPC1 (0.40) | TAS2R8RIPK1CDK5CDK5R1 | |
| SCHEMBL20364376 | 0.80 | TAS2R8 (0.40) | TAS2R8RIPK1CDK5CDK5R1SCD | |
| SCHEMBL20364385 | 0.79 | TAS2R8 (0.52) | TAS2R8RIPK1CDK5CDK5R1WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194773-A1 | BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE | NR0B1, NR2E1, NR0B2 | TAS2R8 2479/4885RIPK1 3470/4885HTR2C 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.